Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its
participation at the Cancer Genomics Consortium (CGC) 2023 Annual
Meeting with a broad range of content covering the utility of
optical genome mapping (OGM) for solid tumor and hematological
malignancy cancer research, including scientific platform and
poster presentations from Bionano and a panel discussion featuring
esteemed researchers from across the cancer genomics landscape.
CGC’s annual meeting brings together industry, medical, and
academic professionals to discuss advances in clinical genomics for
oncology research. CGC conference sessions will be held August
13-16, 2023, online and in-person in St. Louis, Missouri.
As part of a sponsored spotlight panel, Bionano’s chief medical
officer, Dr. Alka Chaubey, will host a discussion titled
“Unleashing Genomic Insights That Matter with Optical Genomic
Mapping: An Interactive Panel Discussion,” featuring cancer
genomics experts Dr. Ravindra Kolhe, from the Medical
College of Georgia/Augusta University, Dr. Yassmine Akkari, from
Nationwide Children’s Hospital, Dr. Susan Crocker, from
Kingston Health Sciences Centre/ Queen’s University, and Dr. Sachin
Jadhav, from HCG Network. During this interactive session, experts
will discuss their experience implementing OGM, key applications,
and potential implications for future clinical research and medical
guidelines. The presentation will take place Monday, August 14,
from 12:30-1:00 PM CDT in the General Session room at the
conference.
Thirteen separate scientific presentations highlighting OGM as a
novel technique in cancer research will be given at the
conference. Presenters from Bionano, Bionano Laboratories,
Augusta University, The University of Texas MD Anderson Cancer
Center, Cincinnati Children’s Hospital Medical Center, University
of Washington, Health Care Global, Children’s Hospital Los
Angeles/USC, Greenwood Genetic Center and Oxford University
Hospitals NHS Foundation Trust will present on the use of OGM in
solid tumor and hematological malignancy research.
In addition, three posters featuring results from OGM
applications in cytogenetics and cancer research will be presented
at the conference.
Scientific presentations from Bionano and collaborators
include:
Session |
Title |
Presenter |
Presented |
Session 1: Applications of Emerging Technologies in Clinical
Genomics |
Application of optical genome mapping to identify samples with
homologous recombination deficiency |
Hastie, A. |
August 13, 20232:15-3:15 PM CDT |
Speed Abstracts Session I: Use of Different Molecular Techniques to
Diagnose Cancer |
Evaluation of Hi-C versus optical genome mapping for diagnosing
constitutional genomic structural variants |
Fang, H. |
August 13, 20236:15-6:45 PM CDT |
Session 4: Clinical Utility of Genomic Testing for Identification
and Potential for Therapy Selection in Solid Tumors |
Optical genome mapping reveals new insights into ZFTA fusion in
supratentorial ependymomas |
Ji, J. |
August 14, 202310:45-11:45 AM CDT |
Speed Abstracts Session II |
Analytical validation of an optical genome mapping assay for the
detection of structural variation in hematologic malignancies as a
lab-developed test |
Sahoo, T. |
August 14, 202311:45 AM-12:15 PM CDT |
Speed Abstracts Session II |
Clinical utility of optical genome mapping: comparison with
standard cytogenomics work-up for hematological malignancies |
Toruner, G. |
August 14, 202311:45 AM-12:15 PM CDT |
Sponsored Session |
Unleashing Genomic Insights That Matter with Optical Genomic
Mapping: An Interactive Panel Discussion |
Chaubey A., Kolhe R., Akkari Y., Crocker S., Jadhav S. |
August 14, 202312:30-1:00 PM CDTGeneral Session Room, Grand
Ballroom EF |
Session 6: Integration of Novel Technologies in the Clinical Cancer
Genomics Laboratory for Improving Patient Care |
Optical genome mapping identifies additional cytogenetic
abnormalities in patients with hematologic malignancies |
Jadhav, S. |
August 14, 20233:30-4:00 PM CDT |
Spotlight Symposium |
ISCN 2024 update including a preview of the new genomic mapping
nomenclature |
Hastings, R. |
August 14, 20235:30-6:00 PM CDT |
Session 8: Value of Novel Technologies for the Identification of
Clonal Aberrations Different from Standard of Care Findings in
Hematologic Malignancies |
Optical genome mapping in hematological malignancy: clinical
outcomes in a 2-year follow-up retrospective study |
Sahajpal, N. |
August 15, 202310:45-11:45 AM CDT |
Session 9: Applications of Emerging Technologies in Clinical
Genomics |
Rare SRY-positive derivative X chromosome in female fetus with
apparently normal development |
Brewer, C. |
August 15, 20232:00-3:00 PM CDT |
Session 9: Applications of Emerging Technologies in Clinical
Genomics |
A novel method for detection of loss of heterozygosity using
B-allele frequency from optical genome mapping data |
Raksi, A. |
August 15, 20232:00-3:00 PM CDT |
The following scientific posters from Bionano and collaborators
will be on display Monday, August 14, from 6:00-7:00 PM CDT in the
exhibit hall:
Title |
Author |
Novel complex translocation causing a PDGFRA-PRKG2 fusion
identified by optical genome mapping in myeloid neoplasm with
basophilia |
Rao, S. |
Atypical BCR-ABL1 rearrangements identified by optical genome
mapping in patients with chronic myeloid leukemia |
Sahoo, T. |
Optical genome mapping for detection of biomarkers in residual
disease monitoring research of hematologic malignancies |
Yu, J. |
“Bionano is pleased to participate in the CGC conference this
year, with a variety of presentations and posters covering the
utility of our solutions for cancer research applications. We are
excited to share our latest product advancements with CGC
conference attendees, including VIA, our new software that offers a
simple and integrated workflow for visualization, interpretation
and reporting for data types including OGM, next-generation
sequencing and microarrays. VIA also features a heme malignancy
workflow, including curated resources that represent
guideline-based targets applicable to hematological disease, which
we believe will make the product particularly relevant for cancer
researchers,” commented Erik Holmlin, PhD, president and chief
executive officer of Bionano.
More details on the conference can be found here:
https://bionano.com/cgc2023/.
About Bionano
Bionano is a provider of genomic analysis solutions that can
help reveal answers to challenging genetic questions. Our mission
is to transform the way the world sees the genome through optical
genome mapping (OGM). Our OGM solutions allow scientists and
clinical researchers the ability to see and discover structural
variations in a way unmatched by traditional cytogenetic
techniques. Our products additionally include an industry-leading,
platform-agnostic software solution, which integrates OGM,
next-generation sequencing and microarray data in one consolidated
view, and nucleic acid extraction and purification solutions using
proprietary isotachophoresis technology. Our Lineagen, Inc., d/b/a
Bionano Laboratories, business provides diagnostic testing for
patients with clinical presentations consistent with autism
spectrum disorder and other neurodevelopmental disabilities. To
learn more, visit bionano.com and connect with us
on Twitter, LinkedIn, Instagram,
and YouTube.
Unless specifically noted otherwise, Bionano products are
provided for Research Use Only. Not for use in diagnostic
procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “believe,” “potential,” “will,” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) convey uncertainty of
future events or outcomes and are intended to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the potential of our OGM workflows or other genomic solutions to be
useful in research applications such as solid tumors, hematological
malignancies, leukemia and basophilia; the ability of our OGM
workflows and other genomic solutions to offer new insights and
address critical gaps left unanswered by other genome analysis
products; OGM’s utility in research, development, and manufacturing
processes for monitoring genomic integrity and off-target
effects in cell lines and its potential to improve the quality,
safety, and overall risk profile of next-generation therapy
development and manufacturing; the utility of OGM for research in
the areas reported in the presentations given and the posters made
available at the CGC annual meeting; the utility, relevance and
benefits of our latest products, including Ionic G2 kits for the
Ionic Purification System and VIA software, for cancer researchers;
and the growth and adoption of OGM for use in
monitoring genomic integrity and off-target effects in cell
lines. Each of these forward-looking statements involves risks and
uncertainties. Actual results or developments may differ materially
from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: global and macroeconomic
events, such as recent and potential bank failures, potential
resurgences of COVID-19 and the ongoing Ukraine-Russian conflict
and related sanctions, on our business and the global economy;
general market conditions; changes in the competitive landscape and
the introduction of competitive technologies or improvements to
existing technologies; failure of our OGM workflows or other
genomic solutions to be useful in research applications such as
solid tumors, hematological malignancies, leukemia and basophilia
or for monitoring genomic integrity and off-target effects in
cell lines and its potential to improve the quality, safety, and
overall risk profile of next-generation therapy development and
manufacturing; failure of OGM to be used or prove useful for
monitoring genomic integrity and off-target effects in cell
lines; failure of researchers to adopt OGM; the ability of our OGM
solutions to offer the anticipated benefits for and contributions
to the areas reported in the presentations given and posters made
available at the CGC annual meeting; future study results
contradicting the results reported in the presentations given and
posters made available at the CGC annual meeting; changes in our
strategic and commercial plans; our ability to obtain sufficient
financing to fund our strategic plans and commercialization
efforts; the ability of medical and research institutions to obtain
funding to support adoption or continued use of our technologies;
and the risks and uncertainties associated with our business and
financial condition in general, including the risks and
uncertainties described in our filings with the Securities and
Exchange Commission, including, without limitation, our Annual
Report on Form 10-K for the year ended December 31, 2022 and in
other filings subsequently made by us with the Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionano.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Jul 2023 to Jul 2024